NO20031531L - Fremgangsmater for induksjon av kreftcelledod og tumorregresjon - Google Patents

Fremgangsmater for induksjon av kreftcelledod og tumorregresjon

Info

Publication number
NO20031531L
NO20031531L NO20031531A NO20031531A NO20031531L NO 20031531 L NO20031531 L NO 20031531L NO 20031531 A NO20031531 A NO 20031531A NO 20031531 A NO20031531 A NO 20031531A NO 20031531 L NO20031531 L NO 20031531L
Authority
NO
Norway
Prior art keywords
methods
cell death
cancer cell
tumor regression
induction
Prior art date
Application number
NO20031531A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031531D0 (no
Inventor
George Q Daley
Original Assignee
George Q Daley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Q Daley filed Critical George Q Daley
Publication of NO20031531D0 publication Critical patent/NO20031531D0/no
Publication of NO20031531L publication Critical patent/NO20031531L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20031531A 2000-10-05 2003-04-04 Fremgangsmater for induksjon av kreftcelledod og tumorregresjon NO20031531L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (2)

Publication Number Publication Date
NO20031531D0 NO20031531D0 (no) 2003-04-04
NO20031531L true NO20031531L (no) 2003-06-05

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031531A NO20031531L (no) 2000-10-05 2003-04-04 Fremgangsmater for induksjon av kreftcelledod og tumorregresjon

Country Status (14)

Country Link
US (1) US6777415B2 (https=)
EP (1) EP1322334A2 (https=)
JP (1) JP2004510733A (https=)
CN (1) CN1479630A (https=)
AU (2) AU1186202A (https=)
BR (1) BR0114430A (https=)
CA (1) CA2424797C (https=)
HK (1) HK1052870A1 (https=)
HU (1) HUP0302913A3 (https=)
MX (1) MXPA03003011A (https=)
NO (1) NO20031531L (https=)
NZ (1) NZ524936A (https=)
WO (1) WO2002028381A2 (https=)
ZA (1) ZA200302523B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
CA2477953A1 (en) * 2002-03-01 2003-09-12 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
JP2007510661A (ja) * 2003-11-06 2007-04-26 シェーリング　コーポレイション 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
JP2009516167A (ja) * 2005-11-11 2009-04-16 ロジャー・ウィリアムズ・ホスピタル 癌処置における予測マーカーとしてのｐ６６−ｓｈｃ
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69120430D1 (de) 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
IL133389A0 (en) 1997-06-17 2001-04-30 Schering Corp Novel n-substituted urea inhibitors of farnesyl-protein transferase
JP2002510308A (ja) 1997-06-17 2002-04-02 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビターとしてのベンゾ（５，６）シクロヘプタ（１，２−ｂ）ピリジン誘導体
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
AU2001294511A1 (en) * 2000-06-30 2002-01-08 The Regents Of The University Of California New strategy for leukemia therapy
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Also Published As

Publication number Publication date
WO2002028381A3 (en) 2003-03-27
CN1479630A (zh) 2004-03-03
AU2002211862B2 (en) 2007-03-15
HUP0302913A3 (en) 2005-05-30
WO2002028381A2 (en) 2002-04-11
US20020128280A1 (en) 2002-09-12
MXPA03003011A (es) 2003-07-14
BR0114430A (pt) 2004-01-06
HK1052870A1 (zh) 2003-10-03
NO20031531D0 (no) 2003-04-04
NZ524936A (en) 2005-08-26
CA2424797A1 (en) 2002-04-11
ZA200302523B (en) 2004-08-24
US6777415B2 (en) 2004-08-17
JP2004510733A (ja) 2004-04-08
HUP0302913A2 (hu) 2003-12-29
EP1322334A2 (en) 2003-07-02
CA2424797C (en) 2009-12-29
AU1186202A (en) 2002-04-15

Similar Documents

Publication Publication Date Title
MY120841A (en) Methods of inducing cancer cell death and tumor regression
NO20031531L (no) Fremgangsmater for induksjon av kreftcelledod og tumorregresjon
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
MY117961A (en) Inhibitors of farnesyl protein transferase
AP1599A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties.
NO963860L (no) Isoprenyl-transferase-inhibitorer
ATE415161T1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
CY1105477T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου
WO2001064252A3 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
WO2001064198A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064195A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
NO20023833L (no) Modifiserte cytokiner for anvendelse i cancerterapi
ES2138595T3 (es) Inhibidores de citoquinas.
DE68903378D1 (de) Hemmung der zellenadhaesion.
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
DE69232596D1 (de) Inhibitor von nebenwirkungen zur krebstherapy
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
WO2001064197A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
DE69305348D1 (de) Proteintyrosinphosphatase alpha - Inhibitoren zur Tumorbehandlung
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
BR0114856A (pt) Combinação compreendendo camptotecina e um derivado de estilbeno para o tratamento de câncer
ECSP003417A (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
NZ509646A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
ECSP982800A (es) Metodos para el tratamiento de enfermedades proliferativas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application